A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood

A Pan-Canadian Validation Study for the Detection of EGFR T790M Mutation Using Circulating Tumor DNA From Peripheral Blood

Introduction: Genotyping circulating tumor DNA (ctDNA) is a promising noninvasive clinical tool to identify the EGFR T790M resistance mutation in patients with advanced NSCLC with resistance to EGFR inhibitors. To facilitate standardization and clinical adoption of ctDNA testing across Canada, we de...

Full description

Bibliographic Details
Main Authors: Shamini Selvarajah, PhD, Sophie Plante, MSc, Marsha Speevak, PhD, Andrea Vaags, PhD, Darren Hamelinck, MSc, Martin Butcher, MSc, Elizabeth McCready, PhD, Daria Grafodatskaya, PhD, Normand Blais, MD, Danh Tran-Thanh, MD, Xiaoduan Weng, MD, Rami Nassabein, MD, Wenda Greer, PhD, Ryan N. Walton, MPH, Bryan Lo, MD, Doug Demetrick, MD, Stephanie Santos, BSc, Bekim Sadikovic, PhD, Xiao Zhang, BSc, MSc, Tong Zhang, MD, Tara Spence, PhD, Tracy Stockley, PhD, Harriet Feilotter, PhD, Philippe Joubert, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
Plasma ctDNA testing
Liquid biopsy
EGFR T790M variant
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000710

Internet

http://www.sciencedirect.com/science/article/pii/S2666364321000710

Similar Items